TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia

Cancer Discovery

Volumn 3, Issue 5, 2013, Pages 564-577

  Sanda, Takaomi ^a   Tyner, Jeffrey W ^d   Gutierrez, Alejandro ^a,b   Ngo, Vu N ^f   Glover, Jason ^d   Chang, Bill H ^d   Yost, Arla ^h   Ma, Wenxue ^g   Fleischman, Angela G ^d   Zhou, Wenjun ^a   Yang, Yandan ⁱ   Kleppe, Maria ^j   Ahn, Yebin ^a   Tatarek, Jessica ^c   Kelliher, Michelle A ^c   Neuberg, Donna S ^a   Levine, Ross L ^j   Moriggl, Richard ^k   Müller, Mathias ^l   Gray, Nathanael S ^a   Jamieson, Catriona H M ^g   Weng, Andrew P ^h   Staudt, Louis M ⁱ   Druker, Brian J ^d,e   Thomas Look, A ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^l UNIVERSITY OF VETERINARY MEDICINE   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 11 RECEPTOR; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 6 RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE TYK2; SHORT HAIRPIN RNA; STAT1 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONING; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; LOSS OF FUNCTION MUTATION; MICROARRAY ANALYSIS; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEQUENCE ANALYSIS; T LYMPHOCYTE; TRANSIENT TRANSFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; HUMANS; INTERLEUKIN-10; JANUS KINASE 3; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PIPERIDINES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; PYRROLES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TYK2 KINASE; TYRPHOSTINS;

EID: 84877595634     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0504     Document Type: Article

References (49)

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-87.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefi tinib. N Engl J Med 2004; 350: 2129-39.
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefi tinib therapy. Science 2004; 304: 1497-500.
5. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669-76.
6. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience. J Clin Oncol 2003; 21: 3616-22.
7. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009; 114: 5136-45.
8. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8: 380-90.
9. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 6306-15.
10. Weng AP, Ferrando AA, Lee W, Morris JPT, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-71.
11. O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, Wong KK, et al. Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med 2007; 204: 3059-66.
12. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879-88.
13. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005; 5: 189-200.
14. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, et al. RNAi screen for rapid therapeutic target identifi cation in leukemia patients. Proc Natl Acad Sci U S A 2009; 106: 8695-700.
15. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-offunction RNA interference screen for molecular targets in cancer. Nature 2006; 441: 106-10.
16. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-31.
17. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-87.
18. Porcu M, Kleppe M, Gianfelici V, Geerdens E, De Keersmaecker K, Tartaglia M, et al. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 2012; 119: 4476-9.
19. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 2008; 22: 1117-24.
20. Wright DD, Sefton BM, Kamps MP. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol Cell Biol 1994; 14: 2429-37.
21. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009; 114: 647-50.
22. NCBI Short Genetic Variations. Available from: http://www.ncbi.nlm. nih.gov/projects/SNP. [cited 2012 Dec 12].
23. 1000 Genomes [cited 2012 Dec 12]. Available at: http://browser.1000 genomes.org.
24. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, et al. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat Immunol 2002; 3: 859-66.
25. Shide K, Shimoda K, Kamezaki K, Kakumitsu H, Kumano T, Numata A, et al. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leuk Res 2007; 31: 1077-84.
26. Ihle JN. The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Semin Immunol 1995; 7: 247-54.
27. Weber-Nordt RM, Henschler R, Schott E, Wehinger J, Behringer D, Mertelsmann R, et al. Interleukin-10 increases Bcl-2 expression and survival in primary human CD34 shematopoietic progenitor cells. Blood 1996; 88: 2549-58.
28. Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology 1997; 92: 1-5.
29. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61: 5137-44.
30. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 2002; 12: 1219-23.
31. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 379: 645-8.
32. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-32.
33. Porcu M, Gielen O, Cools J, De Keersmaecker K. JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines. Haematologica 2009; 94: 435-7.
34. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205: 751-8.
35. Asnafi V, Le Noir S, Lhermitte L, Gardin C, Legrand F, Vallantin X, et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol 2010; 148: 178-9.
36. Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008; 14: 3716-21.
37. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129-33.
38. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112-21.
39. Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T, et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell 2010;18: 353-66.
40. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, et al. Partial impairment of cytokine responses in Tyk2-defi cient mice. Immunity 2000; 13: 549-60.
41. German Mouse Clinic. Available at: http://www.mouseclinic.de/index. php?id p11119.
42. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
43. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, et al. Human tyrosine kinase 2 defi ciency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25: 745-55.
44. Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL, et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood; 115: 1175-84.
45. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000; 95: 2076-83.
46. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, et al. RNAi screening of the tyrosine kinome identifi es therapeutic targets in acute myeloid leukemia. Blood 2008; 111: 2238-45.
47. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001; 98: 31-6.
48. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006; 66: 11156-65.
49. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-74.